Pharmaceutical Technology on MSN
Aktis Oncology kicks 2026 IPO cycle off with $210m target
According to the registration form, Aktis intends to use a large portion of the IPO proceeds on the two programmes. Around ...
Hosted on MSN
2026’s IPO lineup is getting dangerous
Something big is lining up for 2026, and it’s not just another IPO cycle. Wall Street is staring at one of the most crowded public-market queues in years, with 190+ companies racing toward the exit at ...
Outlook Money on MSN
Rush: How to steer your IPO journey
The primary market is buzzing, defying volatility and rewriting records. After nearly 17 years, the number of mainboard ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results